Numerous prospective and retrospective clinical studies have demonstrated the efficacy of a combined regimen of EGFR-TKI and MET-TKI in patients who acquired MET amplification/overexpression during EGFR-TKI therapy.10, 11, 12, 13, 14, 15, 16, 17, 18, 19 However, the optimal first-line treatment strategy for patients with EGFR-mutant and MET-amplified/overexpressed advanced NSCLC remains controversial. Here, MET is linked to non-small cell lung carcinoma.